Sifalimumab

Sifalimumab is a human monoclonal antibody designed for the treatment of SLE, dermatomyositis, and polymyositis.^[1] It targets interferon a.^[2]

Sifalimumab

Fab fragment of sifalimumab bound to IFN-α2A. From PDB: 4ypg​.
Monoclonal antibody
Type	Whole antibody
Source	Human
Target	Interferon α
Clinical data
ATC code	none
Identifiers
CAS Number	1006877-41-3 Y
ChemSpider	none
UNII	XOY1YA7RMC
KEGG	D09668
Chemical and physical data
Formula	C6518H10008N1724O2032S38
Molar mass	146252.08 g·mol−1
NY (what is this?)  (verify)

Sifalimumab was developed by MedImmune; as of 2017 development had been terminated in favor of moving a competing internal product, anifrolumab, into Phase III trials.^[3][4][5]